Contract development and manufacturing organizations (CDMOs) are a crucial part of the life sciences industry. Strangely, despite its current prominence, the CDMO...
Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.
Swiss CDMO Lonza has acquired Dutch-based Synaffix, a biotech focused on ADC development. The deal comprises an initial cash injection of €100 million and up to €60...
The new PBPK modelling service from Lonza combines computer models with experiments to predict a molecule’s PK, and whether solubility problems might need solving.
Swiss CMDO Lonza said it will expand its Early Development Services (EDS) offering into North America with a new laboratory in Cambridge, Massachusetts, set to open in...
As part of its growth strategy, Siegfried strengthens its management team and appoints Christian Dowdeswell as Chief Business Officer Drug Substances and member of the...
